| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
|
Riedel, Richard
|
|
2019
|
133 |
C |
p. 20-22
|
artikel
|
| 2 |
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
|
Liang, Sheng-Kai
|
|
2019
|
133 |
C |
p. 103-109
|
artikel
|
| 3 |
Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting ‘Direct to LAT’ in selected groups
|
Tsim, Selina
|
|
2019
|
133 |
C |
p. 123-129
|
artikel
|
| 4 |
Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies
|
Solassol, J.
|
|
2019
|
133 |
C |
p. 45-47
|
artikel
|
| 5 |
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer
|
Tsakonas, Georgios
|
|
2019
|
133 |
C |
p. 69-74
|
artikel
|
| 6 |
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study
|
Xu, Lisheng
|
|
2019
|
133 |
C |
p. 23-31
|
artikel
|
| 7 |
Contents
|
|
|
2019
|
133 |
C |
p. v-vi
|
artikel
|
| 8 |
Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody
|
Saiki, Masafumi
|
|
2019
|
133 |
C |
p. 4-9
|
artikel
|
| 9 |
Editorial Board
|
|
|
2019
|
133 |
C |
p. iii
|
artikel
|
| 10 |
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials
|
Morabito, Alessandro
|
|
2019
|
133 |
C |
p. 62-68
|
artikel
|
| 11 |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler, Martin
|
|
2019
|
133 |
C |
p. 10-19
|
artikel
|
| 12 |
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes
|
Aredo, Jacqueline V.
|
|
2019
|
133 |
C |
p. 144-150
|
artikel
|
| 13 |
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis
|
Awad, Mark M.
|
|
2019
|
133 |
C |
p. 96-102
|
artikel
|
| 14 |
Inhibition of the Hedgehog pathway in lung cancer
|
Dimou, A.
|
|
2019
|
133 |
C |
p. 56-61
|
artikel
|
| 15 |
Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis
|
Gaye, Elisabeth
|
|
2019
|
133 |
C |
p. 1-3
|
artikel
|
| 16 |
MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells
|
Tada, Makoto
|
|
2019
|
133 |
C |
p. 88-95
|
artikel
|
| 17 |
Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio
|
Shinde, Ashwin
|
|
2019
|
133 |
C |
p. 136-143
|
artikel
|
| 18 |
Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice
|
Ksienski, Doran
|
|
2019
|
133 |
C |
p. 110-116
|
artikel
|
| 19 |
Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy
|
Sakin, Abdullah
|
|
2019
|
133 |
C |
p. 38-44
|
artikel
|
| 20 |
Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients
|
Li, Xiao
|
|
2019
|
133 |
C |
p. 75-82
|
artikel
|
| 21 |
Real-world lung cancer screening decision-making: Barriers and facilitators
|
Lowenstein, Margaret
|
|
2019
|
133 |
C |
p. 32-37
|
artikel
|
| 22 |
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial
|
Peters, S.
|
|
2019
|
133 |
C |
p. 83-87
|
artikel
|
| 23 |
Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer
|
Romero-Vielva, Laura
|
|
2019
|
133 |
C |
p. 117-122
|
artikel
|
| 24 |
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219
|
Melosky, Barbara
|
|
2019
|
133 |
C |
p. 48-55
|
artikel
|
| 25 |
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer
|
Degens, J.H.R.J.
|
|
2019
|
133 |
C |
p. 130-135
|
artikel
|
Tijdschrift beschrijving